Efter aflæggelse af Q4 regnskabet afholdte Coloplast ledelse med analytikerne, deres investorpræsentation som kan ses via dette link. Her har man mulighed for at høre Q&A med analytikerne efter ledelsens indledende præsentation.
Coloplast indleder præsentationen sådan:
2019/20 Highlights
• Organic growth of 4% and 3% reported growth in DKK
• FY organic growth negatively impacted by COVID-19, particularly the
cancellation of elective procedures in Interventional Urology, WC in China
and UK Chronic Care
• Chronic Care business in the US and Emerging markets delivered largely
stable underlying growth throughout the year
• Q4 was negatively impacted by flat growth in several countries in
Europe due to limited growth in new patients, in particular in the UK
Chronic business. Weak quarter in EM due to baseline.
• EBIT before special items grew 5% to DKK 5,854m, corresponding to an
EBIT margin of 32% against 31% last year. This reflects strong cost control
but also sustained investments in growth opportunities and innovation.
• ROIC after tax before special items1 of 46%2
• Year-end dividend of DKK 13.0 per share proposed bringing total dividend
for the year to DKK 18.0 per share
• New “Strive25” strategy presented in September with unchanged long-
term financial guidance of 7-9% organic growth p.a and >30% EBIT margin
• Financial guidance for 2020/21:
• Organic revenue growth of 7-8% and 4-5% reported growth in DKK
• Reported EBIT margin of 31-32% in DKK
• Capex of around DKK 1.1bn, effective tax rate of around 23%
